Karo Bio AB Announces That Merck & Co., Inc. Discontinues Development of Mk-6913 for Hot Flashes
Sep 08, 2010 (NORDIC BUSINESS REPORT via COMTEX) --8 September 2010 - Swedish drug developer Karo Bio AB (STO: KARO) has been notified by its US partner Merck & Co Inc (NYSE: MRK | PowerRating) that it decided to discontinue the development of their joint drug candidate MK-6913 for the treatment of hot flashes.